Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The company’s mission focuses on addressing high unmet medical needs through innovative therapeutic solutions.
At the forefront of Keros’ pipeline is KER-050, a protein therapeutic product candidate aimed at treating low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 is currently in Phase 2 clinical trials, with promising data presented at the 65th American Society of Hematology meeting showcasing its potential to ameliorate ineffective hematopoiesis and improve patient outcomes.
Another key product in development is KER-012, a small molecule being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. This candidate is also in Phase 2 trials and has shown encouraging preliminary results, particularly in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta.
KER-047, another small molecule candidate, targets anemia and the rare genetic disorder, fibrodysplasia ossificans progressiva (FOP). Currently in Phase 1 clinical trials, KER-047 aims to address significant gaps in treatment for these conditions.
Financially, Keros reported a net loss of $39.4 million for the third quarter of 2023, attributed to increased research and development efforts. Despite this, the company maintains a solid cash balance of $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025. The recent public offering of $120 million in common stock further strengthens their financial position.
Keros’ strategic partnerships and collaborations play a crucial role in its development strategy. The company’s agreement with Hansoh (Shanghai) Healthtech Co., Ltd. in 2021 for manufacturing technology transfer is a significant step towards commercial scalability.
The company’s commitment to advancing its pipeline and achieving clinical milestones is evident through its continuous updates and transparent communication with stakeholders. Upcoming milestones include updates on the KER-050 and KER-012 programs, reflecting Keros’ proactive approach in driving innovation and improving patient lives.
Keros Therapeutics remains a leader in leveraging the transforming growth factor-beta (TGF-β) family of proteins, aiming to provide meaningful and potentially disease-modifying benefits to patients.
Keros Therapeutics, Inc. (Nasdaq: KROS) has announced the presentation of results from a preclinical study of KER-012 at the upcoming American Heart Association 2021 Scientific Sessions, scheduled from November 13-15, 2021. KER-012 is designed to inhibit certain ligands that suppress bone growth and is being evaluated for treating conditions like osteogenesis imperfecta, osteoporosis, and pulmonary arterial hypertension (PAH). The abstract indicates the potential of KER-012 to attenuate cardiac pathology in models of right ventricle overload.
Keros Therapeutics, Inc. (KROS) reported a net loss of $20.3 million for Q3 2021, up from $12.0 million in Q3 2020, primarily due to heightened research and development efforts. R&D expenses soared to $14.8 million, reflecting aggressive pipeline advancement. The company is progressing with a Phase 2 trial of KER-050 for myelodysplastic syndromes and has initiated a Phase 1 trial for KER-012. Keros has $221.3 million in cash, expected to support operations through Q4 2023. A clinical data update will be provided at the 63rd ASH Annual Meeting in December.
Keros Therapeutics (Nasdaq: KROS) has announced four abstracts for presentation at the 63rd American Society of Hematology Annual Meeting from December 11-14, 2021. Key highlights include preliminary results from the Phase 2 trial of KER-050 for treating anemia in myelodysplastic syndromes (MDS). The abstracts feature clinical presentations on KER-050's efficacy, along with preclinical data supporting its therapeutic potential for cytopenias. Keros aims to address significant unmet medical needs in hematological disorders with its innovative solutions.
Keros Therapeutics, Inc. (Nasdaq: KROS), presented preclinical results of KER-012 at the ASBMR 2021 Annual Meeting, showcasing its efficacy in preventing bone loss in a rodent pulmonary arterial hypertension (PAH) model. RKER-012 demonstrated significant improvements in bone metrics compared to untreated controls, suggesting its potential for treating secondary osteoporosis related to PAH. KER-012 is designed to promote bone growth by inhibiting transforming growth factor-Beta ligands. The company emphasizes KER-012's therapeutic promise for bone loss disorders.
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company, announced that CEO Jasbir S. Seehra, Ph.D., will participate in two healthcare conferences. The events include the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 11:00 AM ET as a fireside chat, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13 starting at 7:00 AM ET as a corporate presentation. Both presentations will be accessible online and archived on Keros' investor website for 90 days.
Keros Therapeutics, Inc. (KROS) reported significant progress and financial results for Q2 2021, highlighting advancements in their clinical pipeline. The company announced preliminary results from its Phase 2 trial of KER-050, aimed at treating myelodysplastic syndromes. Financially, Keros posted a net loss of $15.6 million for the quarter, up from $10.8 million in Q2 2020, primarily due to increased R&D and administrative expenses. As of June 30, 2021, Keros held $237.1 million in cash, sufficient to fund operations through Q4 2023.
Keros Therapeutics has appointed Simon Cooper as Chief Medical Officer, effective August 2, 2021. Cooper brings extensive experience from companies like Kadmon Holdings and AbbVie. His role will be crucial as Keros advances its clinical pipeline, particularly the promising KER-050 program. He succeeds Claudia Ordonez, who will continue consulting until September 15, 2021. The company focuses on developing novel therapeutics for hematological and musculoskeletal disorders, targeting significant unmet medical needs.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced preliminary results from its Phase 2 trial of KER-050 for treating anemia and thrombocytopenia in patients with myelodysplastic syndromes. As of May 14, 2021, twelve patients were treated, with five achieving significant hematological endpoints. The drug was well tolerated, with no serious drug-related adverse events reported. Based on the results, Keros will extend the trial duration to up to two years and initiate further trial phases. A conference call is scheduled for June 23, 2021, to discuss these findings.
Keros Therapeutics (KROS) presented significant preclinical data at the EHA2021 Virtual Congress, highlighting the efficacy of ALK2 inhibition and the novel therapy KER-050. Studies showed that ALK2 inhibition reduced hepcidin levels and improved iron homeostasis in models of anemia and iron overload. KER-050 exhibited rapid and sustainable effects on erythropoiesis and increased erythropoietin levels, supporting its potential as a treatment for myelodysplastic syndromes and myelofibrosis. Results indicate promising therapeutic avenues for conditions related to elevated hepcidin.
Keros Therapeutics, Inc. (Nasdaq: KROS) announced that its President and CEO, Jasbir S. Seehra, Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 1 at 2:00 PM EST. The presentation will be available via a live webcast and will also be archived on Keros' Investors section for 90 days. Keros focuses on developing innovative treatments for hematological and musculoskeletal disorders, with key product candidates including KER-050 for cytopenias, KER-047 for anemia from iron imbalance, and KER-012 for bone loss and pulmonary arterial hypertension.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
What is Keros Therapeutics’ main focus?
What are the key products in Keros Therapeutics’ pipeline?
What recent achievements has Keros Therapeutics reported?
What is the financial condition of Keros Therapeutics?
How is Keros Therapeutics advancing its clinical trials?
What partnerships does Keros Therapeutics have?
What disorders does KER-050 target?
What is the significance of Fast Track designation for KER-050?
When can we expect updates on KER-012?
What role does the TGF-β family of proteins play in Keros Therapeutics’ research?
